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Abstract
Background: This retrospective cohort study compared the risks of exacerbations and COPD-related healthcare
costs between patients with chronic obstructive pulmonary disease (COPD) initiating tiotropium (TIO) alone and
patients initiating triple therapy with fluticasone-salmeterol combination (FSC) added to TIO.
Methods: Managed-care enrollees who had an index event of ≥ 1 pharmacy claim for TIO during the study period
(January 1, 2003-April 30, 2008) and met other eligibility criteria were categorized into one of two cohorts
depending on their medication use. Patients in the TIO+FSC cohort had combination therapy with TIO and FSC,
defined as having an FSC claim on the same date as the TIO claim. Patients in the TIO cohort had no such FSC
use. The risks of COPD exacerbations and healthcare costs were compared between cohorts during 1 year of
follow-up.
Results: The sample comprised 3333 patients (n = 852 TIO+FSC cohort, n = 2481 TIO cohort). Triple therapy with
FSC added to TIO compared with TIO monotherapy was associated with significant reductions in the adjusted risks
of moderate exacerbation (hazard ratio 0.772; 95% confidence interval [CI] 0.641, 0.930) and any exacerbation
(hazard ratio 0.763; 95% CI 0.646, 0.949) and a nonsignificant reduction in COPD-related adjusted monthly medical
costs.
Conclusions: Triple therapy with FSC added to TIO compared with TIO monotherapy was associated with
significant reductions in the adjusted risks of moderate exacerbation and any exacerbation over a follow-up period
of up to 1 year. These improvements were gained with triple therapy at roughly equal cost of that of TIO alone.
Keywords: chronic obstructive pulmonary disease, pharmacoeconomics, cost, hospitalization, emergency room
visit, pharmacotherapy, exacerbation, add-on therapy, triple therapy
Background
The goals of pharmacologic therapy for chronic obstruc-
tive pulmonary disease (COPD)-to control symptoms,
improve health status, and reduce the frequency of
exacerbations [1]-cannot be met with monotherapy for
many patients. Guidelines on COPD management
recommend the combined use of long-acting bronchodi-
lators and inhaled corticosteroids to optimize outcomes
in patients with inadequate control on monotherapy [1].
Both long-acting bronchodilators (including the anticho-
linergic tiotropium bromide [TIO] and long-acting beta-
agonists [LABAs] such as salmeterol and formoterol)
and combinations of LABAs and inhaled corticosteroids
(ICS) (such as fluticasone-salmeterol [FSC] and budeso-
nide-formoterol) have been shown to improve dyspnea,
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quality of life compared with placebo [2-8]. Further-
more, combination ICS/LABAs have been shown to
reduce exacerbation rates more than either monother-
apy component alone [9-11]. In addition, triple therapy,
which adds an anticholinergic to ICS/LABA combina-
tions, has been associated with greater improvements in
lung function and quality of life and reduced rates of
hospitalization compared with anticholinergic therapy
alone [12-17]. For example, in a randomized, double-
blind, placebo-controlled study of 449 patients with
moderate or severe COPD, addition of FSC to TIO
improved lung function and quality of life and reduced
hospitalization rates, although it did not significantly
reduce the rates of healthcare utilization-defined COPD
exacerbations over a 1-year period [12]. The benefits of
triple therapy over anticholinergic therapy alone have
been attributed to maintenance of airway functioning
through complementary mechanisms (ie, cholinergic
receptor blockade and beta receptor activation) [13,16].
While the efficacy and tolerability of triple therapy have
been evaluated in clinical trials, the effect on COPD out-
comes of triple therapy relative to TIO alone has not
been assessed in the real-world setting (ie, outside the
confines of a controlled clinical trial). Furthermore,
although research on the pharmacoeconomic impact of
FSC and ipratropium has been done [18], the potential
impact of triple therapy relative to TIO alone on health-
care costs has not been assessed. The study reported
herein was conducted to compare the risks of COPD
exacerbations and COPD-related healthcare costs
between patients initiating TIO alone and patients initiat-
ing triple therapy with FSC added to TIO.
Methods
Study design
Figure 1 shows the design of this observational, retro-
spective cohort study. The target population was mana-
ged care enrollees having ≥ 1 pharmacy claim for TIO
during the study period, which extended from January 1,
2003, through April 30, 2008. An index TIO prescription
was defined as the first chronologically occurring phar-
macy claim for TIO during the enrollment period, which
extended from January 1, 2004 through March 30, 2008.
The date of the index TIO prescription was denoted the
index date.T h epre-index period was the 1-year period
before the index date. The post-index period included a
30-day outcome-free period (so named because study out-
comes were not assessed during that period) and a vari-
able-length follow-up period to a maximum of 1 year
during which study outcomes were assessed. The 30-day
outcome-free period was included to provide sufficient
time for the new medication to take effect. The length of
the follow-up period was defined for each patient based
on the first occurrence of any of the following events: >
60-day gap between end of days supply of the preceding
prescription and the fill date of the next consecutive pre-
scription, an exacerbation (defined below) or COPD-
related hospitalization or emergency room visit (defined
below), end of continuous eligibility in the health plan,
end of the study period, or the end of the 1-year follow-
up period. This study was exempt from institutional
review board approval as it was retrospective, did not
involve an intervention, and utilized anonymized data.
Data source
Data were obtained from the IMS LifeLink Health Plans
Claims Database [19], an integrated source of fully adju-
dicated managed-care claims containing data from more
than 90 managed healthcare plans covering more than
60 million lives across the United States. Data available
for each patient include inpatient and outpatient diag-
noses (by International Classification of Diseases 9th
Edition, Clinical Modification [ICD-9-CM] diagnosis
code) and procedures (in Current Procedural Terminol-
ogy, Version 4 [CPT-4] and Healthcare Common Proce-
dure Coding System [HCPCS] formats) and both retail
and mail-order prescription records, which include the
National Drug Code (NDC) code and quantity dispensed.
Charged, allowed, and paid amounts are available for all
services rendered as are dates of service for all claims.
Additional data elements include demographic variables
(age, gender, geographic region), payor type (Medicare,
Medicaid, commercial, self-insured), provider specialty,
and start and stop dates for plan enrollment. The data
are fully de-identified and compliant with the Health
Insurance Portability and Accountability Act (HIPAA).
Sample
The target population was managed-care enrollees who
had an index event of at least one pharmacy claim for TIO
during the study period (January 1, 2003, through April
30, 2008). Additional inclusion criteria were age ≥ 40 years
at the index date, ≥ 1 diagnosis for COPD (ICD-9-CM
codes 490.xx, 491.xx, 492.xx, 496.xx) in any diagnosis field
during the pre-index period or on the index date, ≥ 1
exacerbation (defined below) in the pre-index period, ≥ 1
prescription claim for ipratropium or ipratropium/albu-
terol combination in the pre-index period, ≥ 2p r e s c r i p -
tions for TIO (including the index prescription) during the
post-index period, no prescription for FSC during the pre-
index period, and no exacerbation or hospital/emergency
room visit within 30 days after the index date. ICD-9-CM
code 490.xx, bronchitis not specified as chronic or acute,
was included in an attempt to enhance the validity of the
analysis by capturing patients with chronic bronchitis
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patients had to be continuously eligible to receive health-
care services in the pre-index period and for at least 30
days after the index date. The following conditions occur-
ring in the pre- or post-index period were reasons for
exclusion: respiratory cancer, cystic fibrosis, fibrosis due to
tuberculosis, bronchiectasis, pneumonoconiosis, pulmon-
ary fibrosis, pulmonary tuberculosis.
Patients were categorized on the index date into one of
two cohorts (TIO+FSC or TIO) depending on their med-
ication use. Patients in the TIO+FSC cohort had combi-
nation therapy with TIO and FSC, defined as having an
FSC claim on the same date as the TIO claim. Patients in
the TIO cohort had no FSC use. Patients adding FSC for
the first time after the 30-day outcome-free period were
excluded from the sample to ensure that the TIO cohort
was not also using FSC. Patients assigned to a drug ther-
apy cohort were considered to be using that therapy dur-
ing the entire follow-up period regardless of whether
they switched therapy to another maintenance medica-
tion (ie, LABA or ICS) (< 5% of the sample switched to a
LABA or ICS in the follow-up). While FSC 250 μgi st h e
currently approved daily dose for COPD in the United
States, this study did not exclude from the sample
patients using higher or lower doses of FSC.
Outcomes
The risks of moderate COPD exacerbation and severe
COPD exacerbation were compared between cohorts.
Moderate COPD exacerbation was defined as an emer-
gency room visit with a primary diagnosis code for
COPD, a physician visit with a diagnosis code for COPD
in any field + a prescription for an oral corticosteroid, a
physician visit with a diagnosis code for COPD in any
field + an antibiotic for respiratory infections, or physi-
cian administration of nebulized albuterol within 3 days
following a physician office visit. Severe COPD exacerba-
tion was defined as hospitalization with a primary dis-
charge diagnosis for COPD. When computing the
number of exacerbations, an exacerbation within 45 days
of a previous exacerbation was not counted as a separate
exacerbation [20]. Risks of emergency room visits with a
primary diagnosis code for COPD and hospitalizations
with a primary discharge diagnosis for COPD were also
examined separately in case they were missed in the
count of exacerbations (eg, if they occurred within 45
days of a previous exacerbation). COPD-related total
(medical+pharmacy), medical, and pharmacy costs were
also determined. COPD-related medical costs were com-
puted from the paid amounts of medical claims with a
primary diagnosis code for COPD. COPD-related
Jan 1, 2003 
Study Period: Jan 1, 2003 to Apr 30, 2008 
Mar 30, 2008  Apr 30, 2008
Variable Follow-up period (1 day to 
365 days) 
Outcome 
COPD exacerbations 
COPD-related costs 
Pre-index period (12-
months) 
Jan 1, 2004 
30-day outcome-free 
period 
Demographics 
Overall comorbidity 
Proxy measures of COPD severity 
 
Index Date 
Enrollment period: Index Rx date 
between Jan 1, 2004 to Mar 30, 2008 
Figure 1 Study design.
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COPD-related prescription medications (including antic-
holinergics, short-acting beta agonists, LABAs, ICSs,
combination ICS/LABAs, methylxanthines, oral corticos-
teroids, and antibiotics for respiratory infections) identi-
fied using NDC codes, HCPCS codes beginning with the
letter J, or CPT codes as appropriate.
All study outcomes were assessed during a variable fol-
low-up period as described above. Costs were computed
on a per-month basis because of interpatient differences in
the length of follow-up and were standardized to 2008 US
dollars using the medical component of the Consumer
Price Index.
Cohorts were also compared with respect to pre-treat-
ment characteristics including demographics (age, sex, US
census region), comorbidities during the pre-index-period
(Charlson comorbidity index score [21], asthma), and
proxies for COPD severity during the pre-index period
(number of canisters of inhaled SABAs, number of canis-
ters of inhaled ipratropium, number of prescriptions for
oral corticosteroids, number of classes of maintenance
therapy, use of home oxygen therapy, number of hospitali-
zations/emergency room visits for COPD, presence of an
intensive care unit stay for COPD, number of physician
v i s i t sf o rC O P D ) .A g e ,s e x ,a n dU Sg e o g r a p h i cr e g i o na t
the index date were obtained from enrollment files. The
Dartmouth-Manitoba adaptation of the Charlson comor-
bidity index score [21]-a weighted index of 19 chronic
medical conditions that predict mortality, post-operative
complications, and length of hospital stay-was calculated
for each patient based on diagnoses reported during the
pre-index period. COPD codes that are generally included
in the computing the Charlson index were excluded.
Patients were classified as having asthma if they had ≥ 1
hospitalization or emergency room visit or ≥ 2p h y s i c i a n
visits with a diagnosis of asthma in any field. The number
of canisters of SABA was computed by dividing the quan-
tity dispensed in mg by mg per canister. The use of home
oxygen therapy was categorized as a binary variable (use,
no use) based on CPT codes for home oxygen therapy on
medical claims. The presence of an intensive care unit stay
with a primary diagnosis code for COPD was identified via
revenue codes.
Statistical analysis
Pretreatment characteristics were summarized with
descriptive statistics. Inferential statistics (chi-square test
for categorical variables, t-test or Mann-Whitney test
for continuous variables) were used to quantify differ-
ences between cohorts.
Unadjusted outcomes of COPD-related exacerbations
assessed during the follow-up period were reported as
rate per 100 person-years of follow-up. The log-rank test
was used to assess statistical differences in unadjusted
time to COPD-related exacerbations, and P values were
used to evaluate statistical differences in the unadjusted
rate per 100 person-years of follow-up. Survival analysis
techniques were used to determine differences in time to
COPD-related exacerbations after controlling for all
other baseline covariates. The proportional hazards
assumption was tested using the global test of propor-
tional hazards to assess the appropriateness of a Cox-pro-
portional hazards regression. Hazard ratios from survival
analysis models provided an estimate of the adjusted dif-
ferences in time to COPD-related exacerbations.
Unadjusted costs per month were summarized with
descriptive statistics for all costs and cost components.
Differences in unadjusted costs per month were analyzed
using t-tests or Mann-Whitney tests for all costs and cost
components. Differences between cohorts in adjusted
COPD related total, medical, and pharmacy costs were
assessed using multivariate regression models. A general-
ized linear model (GLM) using a gamma distribution with
a log link was used. This model estimates the adjusted
costs directly, without the need for retransformation,
while simultaneously using log-transformed costs in its
estimation. Because the data were characterized by a sig-
nificant proportion with zero costs and a positively skewed
distribution for those with costs, 2-part models were used
with a logistic model for the first part and a GLM model
for the second part. Adjusted costs estimated from 2-part
models were computed by multiplying the adjusted prob-
ability obtained from the logistic regression model (part 1)
with the predicted cost from the GLM model (part 2).
Covariates included in the model for statistical adjustment
included age, sex, US census region, Charlson comorbidity
index score, asthma diagnosis, and proxies for COPD
severity during the pre-index period (number of canisters
of inhaled short-acting beta agonists, number of canisters
of inhaled ipratropium, number of prescriptions for oral
corticosteroids, number of classes of maintenance therapy,
use of home oxygen therapy, number of hospitalizations/
emergency room visits for COPD, number of physician
visits for COPD, and number of exacerbations). Addition-
ally, models with costs as the dependent variable included
pre-index COPD-related costs.
Results
Sample
T h en u m b e ro fp e r s o n si nt h ed a t a b a s ew i t ha≥ 1p r e -
scription claim for TIO during the study period was
85,153 (Table 1). Of this group, 3333 patients (n = 852
FSC+TIO, n = 2481 TIO) met all eligibility criteria and
comprised the study sample. The most common reason
for exclusion of those with ≥ 1 prescription claim for TIO
during the study period from the study sample was
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Sample Derivation
Total number of patients with ≥ 1 TIO prescription during study period 85,153
Reason for exclusion, n (%)
< 40 years old as of index date 3347 (3.9)
Absence of continuous health plan eligibility 19,743 (23.2)
Absence of ≥ 1 claim with diagnosis code for COPD 29,216 (34.3)
Presence of FSC in the pre-index period 20,510 (24.1)
Presence of exclusionary comorbid conditions 14,448 (17.0)
Absence of index TIO prescription date during enrollment period 219 (0.26)
Absence of COPD-related exacerbation in the pre-index period 61,619 (72.4)
Absence of ipratropium/ipratropium-albuterol in the pre-index period 22,691 (26.7)
Presence of a COPD-related exacerbation or hospital/emergency room visit in 30-day outcome-free period 6317 (7.4)
Follow-up ending during the 30-day outcome-free period 10,779 (12.7)
Final sample, N 3333
Total TIO TIO+FSC P-value
N = 3333 n = 2481 n = 852
Demographics
Mean age, years (SD) 65.7 (10.9) 66.1 (10.9) 64.6 (11.0) 0.0008
Male, n (%) 1565 (47.0%) 1166 (47.0%) 399 (46.8%) 0.9332
Region, n (%)
East 970 (29.1%) 711 (28.7%) 259 (30.4%)
Midwest 1283 (38.5%) 938 (37.8%) 345 (40.5%)
South 560 (16.8%) 404 (16.3%) 156 (18.3%)
West 520 (15.6%) 428 (17.3%) 92 (10.8%)
Comorbidity in pre-index period
Charlson index (mean, SD) 1.98 (2.1) 1.91 (2.1) 2.18 (2.3) 0.0018
Presence of asthma (%) 1084 (32.5%) 757 (30.5%) 327 (38.4%) < .0001
COPD severity in pre-index period
Mean (SD) short-acting beta-agonist canisters 2.38 (5.1) 2.43 (5.0) 2.22 (5.4) 0.3197
Mean (SD) oral corticosteroid prescriptions 2.03 (2.8) 2.09 (2.9) 1.87 (2.3) 0.0253
Mean (SD) ipratropium or ipratropium/albuterol canisters 5.01 (6.9) 5.12 (6.9) 4.72 (6.9) 0.1451
Mean (SD) classes of maintenance medication* 0.48 (0.7) 0.52 (0.7) 0.37 (0.6) < .0001
Use of home oxygen therapy, n (%) 1049 (31.5%) 801 (32.3%) 248 (29.1%) 0.0849
Presence of intensive care unit stay for COPD, n (%) 110 (3.3%) 81 (3.3%) 29 (3.4%) 0.8447
Hospital visits for COPD
n (%) 695 (20.9%) 467 (18.8%) 228 (26.8%) < .0001
Mean (SD) 0.24 (0.5%) 0.22 (0.5%) 0.31 (0.5%) 0.0002
Emergency room visits for COPD
n (%) 769 (23.1%) 570 (23.0%) 199 (23.4%) 0.8193
Mean (SD) 0.30 (0.7%) 0.31 (0.7%) 0.29 (0.6%) 0.3304
Hospital or emergency room visits for COPD
n, (%) 1289 (38.7%) 917 (37.0%) 372 (43.7%) 0.0005
Mean (SD) 0.55 (0.9) 0.53 (0.9) 0.59 (0.8) 0.0813
Mean (SD) number of physician visits for COPD 3.23 (3.6) 3.33 (3.6) 2.93 (3.4) 0.0041
Exacerbations in pre-index period
All, mean (SD) 1.49 (0.8) 1.50 (0.8) 1.45 (0.7) 0.1441
Severe
n (%) 535 (16.1%) 360 (14.5%) 175 (20.5%) < .0001
Mean (SD) 0.18 (0.4) 0.16 (0.4) 0.22 (0.4) 0.0007
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period (72.4%, or 61,619 of the patients excluded)
(Table 1).
Table 1 shows demographics as well as pre-index clini-
cal characteristics, healthcare use, and costs. The cohorts
were generally comparable with some exceptions. The
TIO+FSC cohort was slightly younger and had more
comorbidities than the TIO cohort. During the pre-index
period, severity measures related to medical use tended
to reflect greater COPD severity in the TIO+FSC cohort
whereas severity measures related to pharmacy use
tended to reflect greater severity in the TIO cohort. For
example, more patients in the TIO+FSC cohort than
patients in the TIO cohort had a COPD-related hospitali-
zation (26.8% versus 18.8%, P < 0.001) whereas the num-
ber of oral corticosteroid prescriptions was higher in the
TIO cohort than the TIO+FSC cohort (2.09 versus 1.87,
P =0 . 0 2 5 ) .T h e s ed i f f e r e n c e swere reflected in the costs
such that the TIO cohort had higher pharmacy costs
than the TIO+FSC cohort ($1494 versus $1296, P <
0.001). Medical costs were higher for the TIO+FSC
cohort than the TIO cohort, but the difference was not
statistically significant.
COPD-Related exacerbations
Patients in the TIO cohort had a longer follow-up time
(in days) compared to the TIO+FSC cohort (mean [SD],
median: 143.9 [118.4], 98.0 versus 106.7 [93.4], 66.5).
Table 2 shows unadjusted and adjusted data on COPD-
related exacerbations. After controlling for differences in
baseline covariates between the cohorts, the TIO+FSC
cohort had a 23% lower hazard of experiencing any
COPD-related exacerbation (P = 0.007) and a 24% lower
hazard of experiencing a moderate COPD-related
exacerbation (P = 0.013) during the follow-up period. A
reduction in the adjusted rate of combined hospitaliza-
tion/emergency room visit with TIO+FSC versus TIO
was also found but was not statistically significant.
COPD-Related costs
Table 3 shows unadjusted and adjusted data on COPD-
related costs. Unadjusted COPD-related total cost/
month was significantly lower by ~$200 on average for
the TIO+FSC cohort compared with the TIO cohort, a
difference primarily attributable to a significant differ-
ence in medical cost/month. However, after adjusting
for baseline differences, the lower monthly COPD-
related medical cost/patient found for the TIO+FSC
cohort compared with the TIO cohort ($490 versus
$543, P > 0.05) was not statistically significant, and
COPD-related total costs/month between cohorts were
similar
Discussion
COPD exacerbations are associated with significant risk of
persistent disability and death, incur substantial economic
and clinical burdens in terms of healthcare resource use
and costs, and are a major risk factor for subsequent ser-
ious exacerbations [1,22-27]. This study is, to the authors’
knowledge, the first to assess risk of COPD exacerbations
and COPD-related costs with triple therapy with an ICS/
LABA and TIO compared with TIO monotherapy in the
real-world setting as opposed to the setting of the con-
trolled clinical trial. In this retrospective cohort study
using claims data, initiation of triple therapy by adding
FSC to TIO was associated with a 23% lower adjusted risk
of experiencing any COPD-related exacerbation and a 24%
lower adjusted risk of experiencing a moderate COPD-
related exacerbation during the follow-up period after
controlling for differences in baseline covariates between
the cohorts. While a trend toward a benefit of triple ther-
apy with FSC added to TIO over TIO monotherapy was
observed in this study for severe exacerbations, it was not
statistically significant. Consistent with the latter result,
the risks of hospitalizations, emergency room visits, and
combined hospitalizations and emergency room visits
were lower with triple therapy with FSC added to TIO
than with TIO monotherapy; however, these differences
were not statistically significant. The risk analyses
employed a rigorous approach to censoring variables to
account for treatment discontinuation, loss of enrollment,
and events of interest to ensure that outcomes were not
inappropriately attributed to the treatment groups even
after drug discontinuation.
The exacerbation data from this observational study
extend the evidence base of the effect of triple therapy on
Table 1 Sample Derivation, Demographics, and Pre-Index Clinical Characteristics and Costs (Continued)
Moderate
n (%) 3021 (90.6%) 2274 (91.7%) 747 (87.7%) 0.0006
Mean (SD) 1.31 (0.8) 1.34 (0.9) 1.23 (0.8) 0.0014
Pre-index costs, mean (SD)
Total COPD-related costs $9108 (18,434) $8825 (18,786) $9932 (17,355) 0.1164
COPD-related pharmacy costs $1444 (1625) $1494 (1681) $1296 (1441) 0.0009
COPD-related medical costs $7665 (18,220) $7331 (18,536) $8636 (17,242) 0.0618
*includes ipratropium, ICS, LABA
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of triple therapy versus TIO monotherapy on lung func-
tion have been consistently observed across studies
[12-17,28], findings on the impact of triple therapy versus
TIO monotherapy on exacerbation rates have been
inconsistent [12,15,17]. In a recent 24-week, randomized,
double-blind trial, no differences were found between tri-
ple therapy relative to TIO alone in the rate of healthcare
utilization-defined exacerbations [17]. However, in a
1-year randomized, parallel-group study, triple therapy
relative to TIO alone significantly reduced the number of
healthcare utilization-defined, COPD-related, and all-
cause hospitalizations, but did not significantly reduce
the rate of exacerbations or the time to exacerbation
[12]. Triple therapy relative to TIO alone decreased rates
of severe exacerbations by 62% (p < 0.001) in a 12-week,
randomized, double-blind, parallel-group study of bude-
sonide formoterol [15]. Inconsistencies between clinical
trials in effects of triple therapy versus TIO monotherapy
on exacerbations have been linked to differences in the
operational definitions of exacerbation [29]. In the cur-
rent study, inclusive definitions for moderate exacerba-
tion and, by extension, any exacerbation were employed.
The definition of a moderate COPD exacerbation
included not only emergency room visits, but also physi-
cian visits with a prescription for an oral corticosteroid
or antibiotic for respiratory infections or physician
administration of nebulized albuterol within 3 days of an
office visit. A similarly inclusive definition was used in
recent studies of COPD exacerbations [30-33]. This
broad definition of COPD exacerbations provides a sensi-
tive measure of treatment outcomes and reflects the
spectrum of manifestations of COPD exacerbations in
clinical practice. Severe exacerbations, on the other hand,
were defined more narrowly in the current study as hos-
pitalizations with a primary discharge diagnosis for
COPD. In claims-based analysis, limited data are avail-
able to determine the severity of exacerbations. In this
study, a restrictive definition of exacerbations was
employed to improve accuracy at the risk of sensitivity.
The reduction in risk of event was not associated with
reduced cost. Although a trend toward lower cost with
triple therapy was observed, it was not statistically sig-
nificant. Pharmacy costs, on the other hand, were higher
for the TIO+FSC cohort, but were not significant either,
and the lack of significance can partly be attributed to
Table 2 COPD-Related Adjusted Multivariate Outcomes and Unadjusted Outcomes in the Follow-up Period by Cohort
Adjusted Outcomes
Adjusted Hazard Ratio: TIO+FSC vs TIO (reference cohort: TIO) 95% CI P value
Any exacerbation 0.772 (0.641, 0.930) 0.007
Severe 0.622 (0.328, 1.180) 0.146
Moderate 0.763 (0.646, 0.949) 0.013
COPD-related hospital/emergency room visit 0.742 (0.511, 1.078) 0.118
Hospitalization 0.681 (0.400, 1.159) 0.157
Emergency room visit 0.807 (0.504, 1.293) 0.373
Unadjusted Outcomes: Rate per 100 Person-Years
TIO Alone TIO+FSC P value
n = 2481 n = 852
Any exacerbation 95.58 75.38 0.003
Severe 7.86 5.06 0.171
Moderate 88.65 69.74 0.004
COPD-related hospital/emergency room visit 21.29 15.79 0.070
Hospitalization 11.14 7.43 0.667
Emergency room visit 12.63 9.90 0.213
P values < 0.05 are bolded.
CI = confidence interval
Table 3 COPD-Related Adjusted Multivariate Costs (2008
USD) and Unadjusted Costs Per Month in the Follow-up
Period by Cohort
TIO TIO + FSC P value
n = 2481 n = 852
Adjusted Costs: mean monthly costs per patient (95% CI)
Total $721 ($190-$2005) $721 ($149-$2250) NS
Pharmacy $190 ($67-$379) $223 ($62-$490) NS
Medical $543 ($66-$3543) $490 ($42-$4044) NS
Unadjusted Costs: mean (SD) monthly costs per patient
Total $782 ($3496) $598 ($1579) 0.039
Pharmacy $194 ($220) $206 ($195) 0.113
Medical $588 ($3472) $392 ($1554) 0.026
NS = nonsignificant
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to the TIO alone cohort (mean [SD]: 2.8 [2.6] versus 3.5
[3.3]).
The study is not without limitations. Our primary study
aim was to evaluate triple therapy in the sequential man-
ner recommended by GOLD guidelines (ie, addition of
an inhaled corticosteroid-containing product to existing
long-acting bronchodilator therapy [eg, addition of
LABA/ICS to TIO therapy]). However, the alternate
pathway to triple therapy (ie, initial LABA/ICS therapy
for patients with severe COPD followed by subsequent
addition of TIO) is also possible and is not as infrequent,
as found in our initial data extraction. We found that
24.1% of the total number of TIO users (provided in
Table 1 as presence of FSC in pre-index period) had
LABA/ICS before their first-ever TIO prescription before
any study criteria were applied. We chose to exclude
these patients from our cohort of triple therapy users,
however, as we felt that including the patients who add
TIO versus those who added LABA/ICS in a combined
triple therapy cohort would create a heterogeneous
cohort that would include a mix of very severe patients
and relatively less-severe COPD patients. This would
have the undesirable effect of inadequate adjustment of
potential confounders when comparing to a TIO alone
cohort, given limitations of our data source (in terms of
lack of clinical parameters). We acknowledge that this
alternate pathway of triple therapy is important and
deserves evaluation of triple therapy on its own, but we
chose to exclude these patients to preserve internal valid-
i t yo fo u rs t u d yf i n d i n g sb yc r e a t i n gc o m p a r a b l ec o h o r t s
as much as possible. Future research may want to evalu-
ate both types of triple therapy cohorts. Although ana-
lyses controlled for differences in baseline disease
severity and other baseline characteristics in both
adjusted cost models and risk models in the current
study, such adjustment is necessarily imperfect and does
not obviate the need for further assessment in cohorts
balanced with respect to baseline characteristics. The
possibility remains of residual confounding due to
between-cohort differences in patient characteristics that
were not controlled for in multivariate analysis.
Besides the possibility of residual confounding, other
limitations of this study include potential errors in the
coding of claims, the inability to verify the accuracy of
diagnosis codes, and the absence of a means of assessing
patient compliance. Furthermore, asthma, which is com-
monly comorbid with COPD and often treated similarly,
could not be excluded based on diagnosis codes because
of lack of reversibility information in claims data. The
potential for these biases is inherent in observational
studies. In the event that these biases were operating,
they are likely to have been operating similarly between
cohorts.
Conclusions
In summary, results of this study show that triple ther-
apy with FSC added to TIO compared with TIO mono-
therapy was associated with significant reductions in the
adjusted risks of moderate exacerbation and any exacer-
bation over a follow-up period of up to 1 year and a
nonsignificant reduction in COPD-related adjusted
monthly medical costs. These data from the real-world
setting, considered in the context of data from rando-
mized clinical trials [12-17], provide preliminary support
of the practice of utilizing triple therapy to optimize
outcomes in COPD. The clinical data show that triple
therapy has been associated with greater improvements
in lung function and quality of life and reduced rates of
hospitalization compared with TIO alone [12-14,17].
The results of the current analysis are consistent with
the possibility that these improvements may be gained
with triple therapy at roughly equal cost of that of TIO
alone.
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